Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

Apr 29, 2021

SELL
$2.82 - $5.6 $1,128 - $2,240
-400 Reduced 36.36%
700 $3,000
Q4 2020

Jan 21, 2021

SELL
$2.09 - $3.09 $418 - $618
-200 Reduced 15.38%
1,100 $3,000
Q1 2020

Apr 14, 2020

SELL
$1.9 - $4.98 $1,520 - $3,984
-800 Reduced 38.1%
1,300 $3,000
Q4 2019

Jan 27, 2020

BUY
$3.95 - $5.35 $395 - $535
100 Added 5.0%
2,100 $10,000
Q2 2019

Jul 23, 2019

SELL
$3.98 - $6.2 $1,990 - $3,100
-500 Reduced 20.0%
2,000 $12,000
Q1 2019

Apr 11, 2019

BUY
$2.0 - $4.4 $800 - $1,760
400 Added 19.05%
2,500 $10,000
Q4 2018

Jan 17, 2019

SELL
$1.61 - $3.62 $644 - $1,448
-400 Reduced 16.0%
2,100 $4,000
Q3 2018

Nov 02, 2018

SELL
$2.26 - $3.27 $1,355 - $1,962
-600 Reduced 19.35%
2,500 $8,000
Q2 2018

Jul 27, 2018

SELL
$3.02 - $4.94 $2,718 - $4,446
-900 Reduced 22.5%
3,100 $9,000
Q1 2018

Apr 30, 2018

SELL
$3.46 - $5.14 $4,498 - $6,682
-1,300 Reduced 24.53%
4,000 $16,000
Q4 2017

Feb 01, 2018

SELL
$4.0 - $6.54 $3,600 - $5,886
-900 Reduced 14.52%
5,300 $22,000
Q3 2017

Oct 24, 2017

SELL
$4.99 - $6.57 $3,493 - $4,599
-700 Reduced 10.14%
6,200 $38,000
Q2 2017

Aug 10, 2017

BUY
N/A
6,900
6,900 $43,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Tci Wealth Advisors, Inc. Portfolio

Follow Tci Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.